Sign up Australia
Proactive Investors - Run By Investors For Investors

Uscom achieves first ever cash flow positive quarter

The cash receipts for the quarter is up 41% compared to Q3 2016.
Uscom achieves first ever cash flow positive quarter
Uscom has been consistently investing in product development

Uscom (ASX:UCM) has achieved its first ever cash flow positive quarter, with results for the Q3 2017 quarter demonstrating record cash receipts of $1.41 million.

The cash receipts for the quarter is up 41% on the corresponding quarter in 2016 ($1 million).

This includes customer cash receipts of $0.91 million, up 43% compared to $0.64 million in Q3 2016.

Uscom manufactures and markets the USCOM 1A, the Uscom BP+ and other devices that measures cardiovascular function, detects irregularities and is used to guide treatment.

During the quarter, Uscom had been finalising regulatory submissions for approval of its products for sale in China, Europe and the U.S.

Uscom is a member of a consortium which was recently awarded a European scientific research grant to promote pulmonary recovery training and drug uptake under the Eurostars program.

The total value of the project is $1.86 million and Uscom will receive $492,000 over the next two years.

The company had a cash balance of $2.13 million as at 31 March 2017.

Uscom has been consistently investing in acquisitions and new product development, and is now poised for accelerated revenue growth.



Register here to be notified of future UCM Company articles
View full UCM profile

Uscom Timeline

Newswire
May 13 2014

Related Articles

test tubes in a laboratory
March 22 2017
It’s hived off its skin division, bolstered its board and has already won new business contracts worth €5.7mln so far this year
Harley Street London street sign
May 27 2016
The cancer treatment specialist has received funding to bring its breakthrough therapy to London.
shutterstock_127456451.jpg
March 30 2017
PIFA Heparin PF/4 - a diagnostic test for allergic reactions to blood thinning agent Heparin - achieved an 85% jump in sales in 2016

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use